The utility of STAT6 and ALDH1 expression in the differential diagnosis of solitary fibrous tumor versus prostate-specific stromal neoplasms
| Autor: | David J. Zahavi, Justin A. Bishop, Jonathan I. Epstein, Rajni Sharma, Maria Angelica Mendoza Rodriguez, Diana Taheri, Stephania M. Bezerra, Gunes Guner, George J. Netto |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male Solitary fibrous tumor Pathology medicine.medical_specialty Stromal cell Aldehyde Dehydrogenase 1 Family Pathology and Forensic Medicine Diagnosis Differential 03 medical and health sciences 0302 clinical medicine Prostate Predictive Value of Tests parasitic diseases Biomarkers Tumor Medicine Humans Aged Aged 80 and over integumentary system business.industry Prostatic Neoplasms Reproducibility of Results Retinal Dehydrogenase Sarcoma respiratory system Middle Aged medicine.disease Immunohistochemistry Staining Isoenzymes 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Solitary Fibrous Tumors Monoclonal Differential diagnosis Stromal Cells business STAT6 Transcription Factor Immunostaining |
| Zdroj: | Human pathology. 54 |
| ISSN: | 1532-8392 1995-2015 |
| Popis: | Solitary fibrous tumor (SFT) diagnosis in prostate can be challenging on small biopsies. Prostatic stromal tumors of unknown malignant potential (STUMP) and SFT have overlapping features. NAB2-STAT6 gene fusions that were recently identified in various SFTs lead to nuclear translocalization of STAT6. Nuclear STAT6 immunostaining is now considered an adjunct for SFT diagnosis. We evaluated STAT6 and an emerging stemness marker, ALDH1, in the differential diagnosis of SFT versus prostatic stromal lesions. Sixteen STUMPs, 12 SFTs, and 4 prostatic stromal sarcomas (12 needle biopsies, 13 radical prostatectomies, 7 transurethral resections) were retrieved (1995-2015). Sections were stained with polyclonal STAT6 antibody (Santa Cruz Biotechnology, Santa Cruz, CA; S20, 1:100) and monoclonal ALDH1 antibody (BD Biosciences, San Jose, CA; clone 44, 1:250). In STAT6 cases, only unequivocal nuclear staining (with/without cytoplasmic staining) was considered positive. Cytoplasmic ALDH1 staining was counted positive. Ten of 11 evaluable SFTs demonstrated strong and diffuse nuclear STAT6 positivity; 4 of 16 STUMPs had nuclear staining that was weak (1/4) or focal (1/4). ALDH1 positivity was seen in 10 of 12 evaluable SFTs and 3 of 15 STUMPs. Prostatic stromal sarcomas were STAT6 negative (4/4); 2 of 4 were ALDH1 positive. The sensitivity and specificity for STAT6 for the diagnosis of SFT were 91% and 75%, respectively. Coexpression of STAT6 and ALDH1 yielded the same sensitivity but improved the specificity (100%) for the diagnosis of SFT. STAT6 is a useful marker in the differential diagnosis of SFT versus STUMP. Using STAT6 and ALDH1 together increases specificity. STUMPs can show STAT6 positivity, and when they do, it is likely to be weak or focal. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect